US Archives - Page 50 of 80 - European Medical Journal

Workload Control Linked to Physician Burnout

Control over clinical work plays a critical role in preventing burnout and retaining U.S. physicians, as highlighted in a new study.

Colorectal Cancer Stool Testing in Underserved Communities

Mailed fecal immunochemical testing (FIT) kits using centralized outreach significantly increases colorectal cancer (CRC) screening rates in underserved communities, according to the results of a new study.

Clonazepam Recall Due To Strength Mislabeling

Clonazepam has been recalled due to potential product carton strength mislabeling. Endo Pharmaceuticals (Malvern, Pennsylvania) has issued a voluntary, nationwide recall of a specific lot of Clonazepam Orally Disintegrating Tablets (USP, C-IV).

How Medical AI Bias Risks Patient Care

Bias in medical artificial intelligence (AI) poses a critical threat to equitable patient outcomes, according to recent research.

How Gut Bacteria Impact Tamoxifen Therapy

The response to tamoxifen, a cornerstone drug in preventing breast cancer recurrence, may hinge on an unexpected factor: gut bacteria.

PAH: A Growing Challenge in Aging Populations

Pulmonary arterial hypertension (PAH), a rare yet life-threatening vascular condition, predominantly affects older adults and women, according to new findings from the Global Burden of Disease Study 2021.

Hypervirulent Drug Resistance Emerges from Ukraine War

Pandrug-resistant Klebsiella pneumoniae strains isolated from Ukrainian war victims are raising red flags for healthcare professionals worldwide.

Long-Term Cognitive Impact of Anti-NMDAR Encephalitis

Long-term cognitive and psychosocial challenges faced by individuals recovering from anti-NMDAR encephalitis, despite many regaining independence, have been highlighted in a recent study.

The Key Role of Partners in Rheumatoid Arthritis Care

The way couples manage stress together profoundly impacts outcomes for patients with rheumatoid arthritis (RA), according to a new study.

Targeted IL-23 Therapy: Phase III Psoriasis Study Findings

Results from the Phase III ICONIC-LEAD trial reveal that JNJ-2113 (icotrokinra, Johnson & Johnson, New Jersey), an oral peptide targeting the IL-23 receptor, demonstrated improvements in skin clearance among patients with moderate to severe plaque psoriasis.